Compound Screening Assays
Assess therapeutic immunogenicity with optimized compound screening assays
Therapeutic lead optimization is a critical and challenging step in drug development that’s often a complex and time-consuming procedure when assessing primary immune cells.
Our suite of primary immune cell screening ImmuSignature™ assays can screen compounds in an in-vitro simulated immune microenvironment, helping move hits into high-quality leads.
These standardized assays have been specifically developed and validated to provide data from 4 weeks and feature:
- Extensive primary immune cell QC
- Statistically robust data sets
- Multiple physiological readouts
- HTRF® technology
- Miniaturized semi-automated 3854 well platform
Mixed Lymphocyte Reaction (MLR) assay
Rapidly identify agents that modulate APC-mediated T cell activation in high-throughput.
T Cell Activation (TCA) assay
Isolate the effect of compounds that promote or block cell proliferation and T-cell activity.
iTreg suppression assay
Efficiently identify therapeutic candidates that influence the suppression of T effector cells.
iTreg polarization assay
Assess the impairment of T Lymphocyte regulatory cells and the effectiveness of therapeutic candidates.
Questions?
We’re here to help.
Contact us Please note that product labeling (such as kit insert, product label, and kit box) may be different compared to the company branding. Please contact your local representative for further details.